Topo I-APC+ topo I-PE+ CD19+ cells in the topo I-induced SSc model mice treated with the BTK inhibitor had higher frequencies of IL-10 and IL-35-producing cells and also produced the significantly higher amount of IL-10 and IL-35 (p<0.005; Figure 7C and D). This evidence concerns the gene BTK and systemic sclerosis.